Loading clinical trials...
Loading clinical trials...
A Phase II Study of VAD (Vincristine, Adriamycin, Dexamethasone) Plus Thalidomide (Low Dose) as Frontline Therapy for Newly Diagnosed Patients With Multiple Myeloma (MM)
Conditions
Interventions
dexamethasone
doxorubicin hydrochloride
+2 more
Locations
1
United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Start Date
August 1, 2004
Primary Completion Date
April 1, 2006
Last Updated
October 3, 2022
NCT01137825
NCT07319897
NCT00049673
NCT00305812
NCT00003353
NCT00002878
Lead Sponsor
Roswell Park Cancer Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions